Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Neil Stuart Horowitz, M.D.

TitleAssistant Professor of Obstetrics, Gynecology and Reproductive Biology
InstitutionBrigham and Women's Hospital
DepartmentObstetrics Gynecology & Repro. Bio.
AddressBrigham and Womens Hospital
Ob Gyn
75 Francis St
Boston MA 02115

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Worley MJ, Guseh SH, Rauh-Hain JA, Williams KA, Muto MG, Feltmate CM, Berkowitz RS, Horowitz NS. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery? Gynecol Oncol. 2013 Apr; 129(1):69-73.
    View in: PubMed
  2. Rauh-Hain JA, Nitschmann CC, Worley MJ, Bradford LS, Berkowitz RS, Schorge JO, Campos SM, Del Carmen MG, Horowitz NS. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol. 2013 Apr; 129(1):63-8.
    View in: PubMed
  3. Campos SM, Penson RT, Matulonis U, Horowitz NS, Whalen C, Pereira L, Tyburski K, Roche M, Szymonifka J, Berlin S. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol. 2013 Feb; 128(2):215-20.
    View in: PubMed
  4. Quick CM, May T, Horowitz NS, Nucci MR. Low-grade, low-stage endometrioid endometrial adenocarcinoma: a clinicopathologic analysis of 324 cases focusing on frequency and pattern of myoinvasion. Int J Gynecol Pathol. 2012 Jul; 31(4):337-43.
    View in: PubMed
  5. Horowitz NS, Olawaiye AB, Borger DR, Growdon WB, Krasner CN, Matulonis UA, Liu JF, Lee J, Brard L, Dizon DS. Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. Gynecol Oncol. 2012 Oct; 127(1):141-6.
    View in: PubMed
  6. Siegel CL, Andreotti RF, Cardenes HR, Brown DL, Gaffney DK, Horowitz NS, Javitt MC, Lee SI, Mitchell DG, Moore DH, Rao GG, Royal HD, Small W, Varia MA, Yashar CM. ACR Appropriateness Criteria® pretreatment planning of invasive cancer of the cervix. J Am Coll Radiol. 2012 Jun; 9(6):395-402.
    View in: PubMed
  7. Esselen KM, Rodriguez N, Growdon W, Krasner C, Horowitz NS, Campos S. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy. Gynecol Oncol. 2012 Oct; 127(1):51-4.
    View in: PubMed
  8. Shah NT, Barroilhet L, Berkowitz RS, Goldstein DP, Horowitz N. A cost analysis of first-line chemotherapy for low-risk gestational trophoblastic neoplasia. J Reprod Med. 2012 May-Jun; 57(5-6):211-8.
    View in: PubMed
  9. Growdon WB, Rauh-Hain JJ, Cordon A, Garrett L, Schorge JO, Goodman A, Boruta DM, Horowitz NS, del Carmen MG. Prognostic determinants in patients with stage I uterine papillary serous carcinoma: a 15-year multi-institutional review. Int J Gynecol Cancer. 2012 Mar; 22(3):417-24.
    View in: PubMed
  10. Rauh-Hain JA, Winograd D, Growdon WB, Schorge JO, Goodman AK, Boruta DM, Berkowitz RS, Horowitz NS, Del Carmen MG. Prognostic determinants in patients with uterine and ovarian clear carcinoma. Gynecol Oncol. 2012 May; 125(2):376-80.
    View in: PubMed
  11. Rodriguez N, Rauh-Hain JA, Shoni M, Berkowitz RS, Muto MG, Feltmate C, Schorge JO, Del Carmen MG, Matulonis UA, Horowitz NS. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2012 May; 125(2):362-6.
    View in: PubMed
  12. Horowitz N, Matulonis UA. New biologic agents for the treatment of gynecologic cancers. Hematol Oncol Clin North Am. 2012 Feb; 26(1):133-56.
    View in: PubMed
  13. Campos SM, Berlin S, Matulonis UA, Muto MG, Pereira L, Mosquera MM, Horowitz N. Young women diagnosed with early-stage ovarian cancer or borderline malignancy of the ovary: a focus on fertility and sexual function. J Psychosoc Oncol. 2012; 30(4):387-401.
    View in: PubMed
  14. Horowitz NS. Management of adnexal masses in pregnancy. Clin Obstet Gynecol. 2011 Dec; 54(4):519-27.
    View in: PubMed
  15. Rungruang B, Miller A, Richard SD, Hamilton CA, Rodriguez N, Bookman MA, Maxwell GL, Krivak TC, Horowitz NS. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Jan; 124(1):53-8.
    View in: PubMed
  16. Rauh-Hain JA, Rodriguez N, Growdon WB, Goodman AK, Boruta DM, Horowitz NS, del Carmen MG, Schorge JO. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann Surg Oncol. 2012 Mar; 19(3):959-65.
    View in: PubMed
  17. Lee JH, Dubinsky T, Andreotti RF, Cardenes HR, Dejesus Allison SO, Gaffney DK, Glanc P, Horowitz NS, Jhingran A, Lee SI, Puthawala AA, Royal HD, Scoutt LM, Small W, Varia MA, Zelop CM. ACR appropriateness Criteria® pretreatment evaluation and follow-up of endometrial cancer of the uterus. Ultrasound Q. 2011 Jun; 27(2):139-45.
    View in: PubMed
  18. Rauh-Hain JA, Growdon WB, Rodriguez N, Goodman AK, Boruta DM, Schorge JO, Horowitz NS, del Carmen MG. Carcinosarcoma of the ovary: a case-control study. Gynecol Oncol. 2011 Jun 1; 121(3):477-81.
    View in: PubMed
  19. Brown DL, Andreotti RF, Lee SI, Dejesus Allison SO, Bennett GL, Dubinsky T, Glanc P, Horrow MM, Lev-Toaff AS, Horowitz NS, Podrasky AE, Scoutt LM, Zelop CM. ACR appropriateness criteria© ovarian cancer screening. Ultrasound Q. 2010 Dec; 26(4):219-23.
    View in: PubMed
  20. Rauh-Hain JA, Growdon WB, Schorge JO, Goodman AK, Boruta DM, McCann C, Horowitz NS, del Carmen MG. Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma. Gynecol Oncol. 2010 Nov; 119(2):299-304.
    View in: PubMed
  21. Duska LR, Garrett L, Henretta M, Ferriss JS, Lee L, Horowitz N. When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. Gynecol Oncol. 2010 Mar; 116(3):374-7.
    View in: PubMed
  22. Rauh-Hain JA, Costaaggini I, Olawaiye AB, Growdon WB, Horowitz NS, del Carmen MG. A comparison of outcome in patients with stage 1 clear cell and grade 3 endometrioid adenocarcinoma of the endometrium with and without adjuvant therapy. Eur J Gynaecol Oncol. 2010; 31(3):284-7.
    View in: PubMed
  23. Rauh-Hain JA, del Carmen M, Horowitz NS, Alarcon IA, Ko E, Goodman AK, Olawaiye AB. Impact of bowel obstruction at the time of initial presentation in women with ovarian cancer. BJOG. 2010 Jan; 117(1):32-8.
    View in: PubMed
  24. Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010 Jan 1; 28(1):154-9.
    View in: PubMed
  25. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009 Nov 20; 27(33):5601-6.
    View in: PubMed
  26. Boyce EA, Costaggini I, Vitonis A, Feltmate C, Muto M, Berkowitz R, Cramer D, Horowitz NS. The epidemiology of ovarian granulosa cell tumors: a case-control study. Gynecol Oncol. 2009 Nov; 115(2):221-5.
    View in: PubMed
  27. Horowitz NS, Goldstein DP, Berkowitz RS. Management of gestational trophoblastic neoplasia. Semin Oncol. 2009 Apr; 36(2):181-9.
    View in: PubMed
  28. Lee L, Garrett L, Lee H, Oliva E, Horowitz N, Duska LR. Association of clear cell carcinoma of the endometrium with a high rate of venous thromboembolism. J Reprod Med. 2009 Mar; 54(3):133-8.
    View in: PubMed
  29. Matulonis UA, Krag KJ, Krasner CN, Atkinson T, Horowitz NS, Lee H, Penson RT. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors. Gynecol Oncol. 2009 Feb; 112(2):394-9.
    View in: PubMed
  30. Matulonis UA, Horowitz NS, Campos SM, Lee H, Lee J, Krasner CN, Berlin S, Roche MR, Duska LR, Pereira L, Kendall D, Penson RT. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 Dec 10; 26(35):5761-6.
    View in: PubMed
  31. Growdon WB, Boisvert SL, Akhavanfard S, Oliva E, Dias-Santagata DC, Kojiro S, Horowitz NS, Iafrate AJ, Borger DR, Rueda BR. Decreased survival in EGFR gene amplified vulvar carcinoma. Gynecol Oncol. 2008 Nov; 111(2):289-97.
    View in: PubMed
  32. Nagymanyoki Z, Growdon WB, Sarno J, Callahan MJ, Parast MM, Fulop V, Mok SC, Horowitz N, Berkowitz RS. Vascularization and expression of angiogenic factors in partial and complete molar pregnancies. J Reprod Med. 2008 Aug; 53(8):589-94.
    View in: PubMed
  33. Sebastian S, Lee SI, Horowitz NS, Scott JA, Fischman AJ, Simeone JF, Fuller AF, Hahn PF. PET-CT vs. CT alone in ovarian cancer recurrence. Abdom Imaging. 2008 Jan-Feb; 33(1):112-8.
    View in: PubMed
  34. Miller JC, Horowitz NS, Thrall JH, Lee SI. Evaluating adnexal lesions: which need follow-up? J Am Coll Radiol. 2007 Oct; 4(10):725-9.
    View in: PubMed
  35. Horowitz NS, Hua J, Powell MA, Gibb RK, Mutch DG, Herzog TJ. Novel cytotoxic agents from an unexpected source: bile acids and ovarian tumor apoptosis. Gynecol Oncol. 2007 Nov; 107(2):344-9.
    View in: PubMed
  36. Gius D, Funk MC, Chuang EY, Feng S, Huettner PC, Nguyen L, Bradbury CM, Mishra M, Gao S, Buttin BM, Cohn DE, Powell MA, Horowitz NS, Whitcomb BP, Rader JS. Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates. Cancer Res. 2007 Aug 1; 67(15):7113-23.
    View in: PubMed
  37. Olawaiye A, Lee LM, Krasner C, Horowitz N. Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva. Gynecol Oncol. 2007 Sep; 106(3):628-30.
    View in: PubMed
  38. Hoffman KE, Horowitz NS, Russell AH. Healing of vulvo-vaginal radionecrosis following revascularization. Gynecol Oncol. 2007 Jul; 106(1):262-4.
    View in: PubMed
  39. del Carmen MG, Findley M, Muzikansky A, Roche M, Verrill CL, Horowitz N, Seiden MV. Demographic, risk factor, and knowledge differences between Latinas and non-Latinas referred to colposcopy. Gynecol Oncol. 2007 Jan; 104(1):70-6.
    View in: PubMed
  40. Vaidya AP, Horowitz NS, Oliva E, Halpern EF, Duska LR. Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma. Gynecol Oncol. 2006 Nov; 103(2):684-7.
    View in: PubMed
  41. Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecol Oncol. 2006 Oct; 103(1):212-8.
    View in: PubMed
  42. Krasner CN, Roche M, Horowitz NS, Supko JG, Lee SI, Oliva E. Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis. N Engl J Med. 2006 Apr 13; 354(15):1615-25.
    View in: PubMed
  43. Horowitz NS, Duska LR. Advances in the surgical management of ovarian cancer. J Reprod Med. 2005 Jun; 50(6):454-66.
    View in: PubMed
  44. Horowitz NS, Dehdashti F, Herzog TJ, Rader JS, Powell MA, Gibb RK, Grigsby PW, Siegel BA, Mutch DG. Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol. 2004 Dec; 95(3):546-51.
    View in: PubMed
  45. Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecol Oncol. 2004 Jul; 94(1):67-73.
    View in: PubMed
  46. Horowitz NS, Powell MA, Drescher CW, Smith MR, Atwood M, Mate TA, Peters WA. Adequate staging for uterine cancer can be performed through Pfannenstiel incisions. Gynecol Oncol. 2003 Mar; 88(3):404-10.
    View in: PubMed
  47. Wright JD, Horowitz, NS. Gynecologic Oncology. Washington University Hematology and Oncology Consult Manual. Editors: Chanter M, Pillot G, Lin T. 2003; 197-203.
  48. Horowitz N, et al. Survival GYN/ONC. Washington University Obstetrics and Gynecology Survival Guide. Editors: Wright JD, Wyatt S, Lin T. 2003; 293-349.
  49. Cohn DE, Horowitz NS, Mutch DG, Kim SM, Manolitsas T, Fowler JM. Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer? Gynecol Oncol. 2002 Dec; 87(3):243-6.
    View in: PubMed
  50. Wright JD, Powell MA, Horowitz NS, Huettner PC, White F, Herzog TJ. Placental site trophoblastic tumor presenting with a pneumothorax during pregnancy. Obstet Gynecol. 2002 Nov; 100(5 Pt 2):1141-4.
    View in: PubMed
  51. Wright JD, Horowitz NS, Rader JS. Primary peritoneal carcinoma presenting as adenocarcinoma on a Pap smear. A case report. J Reprod Med. 2002 Nov; 47(11):933-5.
    View in: PubMed
  52. Horowitz NS, Cohn DE, Herzog TJ, Mutch DG, Rader JS, Bhalla S, Gibb RK. The significance of pneumatosis intestinalis or bowel perforation in patients with gynecologic malignancies. Gynecol Oncol. 2002 Jul; 86(1):79-84.
    View in: PubMed
  53. Horowitz N, Pinto K, Mutch DG, Herzog TJ, Rader JS, Gibb R, Bocker-Edmonston T, and Goodfellow PJ. Microsatellite instability, hMLH1 methylation, and loss of mismatch repair in endometrial carcinoma and atypical hyperplasia. Gynecologic Oncology. 2002; 86(1):62-68.
  54. Horowitz N, Pinto K, Mutch DG, Herzog TJ, Rader JS, Gibb R, Bocker-Edmonston T, Goodfellow PJ. Microsatellite instability, MLH1 promoter methylation, and loss of mismatch repair in endometrial cancer and concomitant atypical hyperplasia. Gynecol Oncol. 2002 Jul; 86(1):62-8.
    View in: PubMed
  55. Horowitz NS, Gibb RK, Menegakis NE, Mutch DG, Rader JS, Herzog TJ. Utility and cost-effectiveness of preoperative autologous blood donation in gynecologic and gynecologic oncology patients. Obstet Gynecol. 2002 May; 99(5 Pt 1):771-6.
    View in: PubMed
  56. Horowitz NS, Peters WA, Smith MR, Drescher CW, Atwood M, Mate TP. Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma. Obstet Gynecol. 2002 Feb; 99(2):235-40.
    View in: PubMed
  57. Horowitz NS, Rader JS. Role of the ultrasonic surgical aspirator in gynecology. Obstet Gynecol Clin North Am. 2001 Dec; 28(4):775-90.
    View in: PubMed
  58. Horowitz NS, Tamimi HK, Goff BA, Koh WJ, Schmidt RA, Greer BE, Paley PJ. Pretreatment scalene node biopsy in gynecologic malignancy: prudent or passé? Gynecol Oncol. 1999 Nov; 75(2):238-41.
    View in: PubMed
  59. Horowitz N, Cohn DE, Luna JA, Winter TJ, Tamimi HK. . Intraoperative ultrasound in the management of ovarian germ cell tumors. Journal Gynecol Tech. 1999; 5:91-94.
  60. Horowitz NS, Staats HF, Palker TJ. Effect of bismuth salts on systemic and mucosal immune responses to orally administered cholera toxin. Immunopharmacology. 1995 Nov; 31(1):31-41.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Horowitz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (271) concept(s)
_
Co-Authors
See all (46) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_